Among patients with non–large vessel occlusion acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase, a ...
Although the recent decision of the British High Court to revoke Genentech’s U.K. patent covering human tissue plasminogen activator is open to appeal, the legal issues have been clearly drawn in a ...
Among patients with non–large vessel occlusion acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase, a modified human tissue plasminogen activator, administered 4.5 to 24 hours ...
The success of biopharmaceuticals started about 30 years ago with the first production of recombinant human insulin (Humulin ®) in Escherichia coli, followed by the first production of human tissue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results